Prodiame
Clinical data
Other names17β-((3-aminopropyl)amino)estradiol; 17β-[(3-Aminopropyl)amino]estra-1,3,5(10)-trien-3-ol; N-(3-Hydroxyestra-1,3,5(10)-triene-1,3-17beta)-1,3-propylenediamine
Identifiers
  • (8R,9S,13S,14S,17S)-17-(3-Aminopropylamino)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H32N2O
Molar mass328.500 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2NCCCN)CCC4=C3C=CC(=C4)O
  • InChI=1S/C21H32N2O/c1-21-10-9-17-16-6-4-15(24)13-14(16)3-5-18(17)19(21)7-8-20(21)23-12-2-11-22/h4,6,13,17-20,23-24H,2-3,5,7-12,22H2,1H3/t17-,18-,19+,20+,21+/m1/s1
  • Key:ZIKAQUBYTJAACW-MJCUULBUSA-N

Prodiame, also known as 17β-((3-aminopropyl)amino)estradiol, is a synthetic, steroidal estrogen and a 17β-aminoestrogen with anticoagulant effects that was first described in 1983 and was never marketed.[1][2]

References

  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1023–. ISBN 978-1-4757-2085-3.
  2. ^ Rubio-Póo C, Mandoki JJ, Jayme V, Mendoza-Patiño N, Alvarado C, Silva G, Zavala E, Fernández-González JM, Rubio-Arroyo M (1983). "Prodiame: a new estrogen with sustained anticoagulant effect". Proc. West. Pharmacol. Soc. 26: 111–3. PMID 6889323.


Categories